Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Harvard Business School
Merck
Baxter
McKinsey

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR CUROSURF


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Curosurf

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00501982 ↗ Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study Completed Chiesi Farmaceutici S.p.A. Phase 4 2007-03-01 The primary objective of this study is to compare two methods of post-delivery stabilization and subsequent early respiratory care for reducing the need for MV and related secondary complications, such as BPD, in premature babies at high risk of RDS: 1. Early stabilization on nCPAP 2. Intubation, prophylactic surfactant (Curosurf®) administration shortly after delivery, and rapid extubation to nCPAP. The data obtained from this comparison will be applied to test the hypothesis that preterm neonates at risk of RDS who are treated with prophylactic surfactant + nCPAP show less need for MV when compared to infants who receive nCPAP alone.
NCT00751959 ↗ Surfactant Application During Spontaneous Breathing With Continuous Positive Airway Pressure (CPAP) in Premature Infants < 27 Weeks Completed Altona Children's Hospital N/A 2009-04-01 This study investigates the efficacy of surfactant application during spontaneous breathing with CPAP in avoiding death and chronic lung disease (CLD) in very immature infants with a gestational age of less than 27 weeks.
NCT00751959 ↗ Surfactant Application During Spontaneous Breathing With Continuous Positive Airway Pressure (CPAP) in Premature Infants < 27 Weeks Completed Asklepios Kliniken Hamburg GmbH N/A 2009-04-01 This study investigates the efficacy of surfactant application during spontaneous breathing with CPAP in avoiding death and chronic lung disease (CLD) in very immature infants with a gestational age of less than 27 weeks.
NCT00751959 ↗ Surfactant Application During Spontaneous Breathing With Continuous Positive Airway Pressure (CPAP) in Premature Infants < 27 Weeks Completed Charite University, Berlin, Germany N/A 2009-04-01 This study investigates the efficacy of surfactant application during spontaneous breathing with CPAP in avoiding death and chronic lung disease (CLD) in very immature infants with a gestational age of less than 27 weeks.
NCT00751959 ↗ Surfactant Application During Spontaneous Breathing With Continuous Positive Airway Pressure (CPAP) in Premature Infants < 27 Weeks Completed DRK Kinderklinik Siegen N/A 2009-04-01 This study investigates the efficacy of surfactant application during spontaneous breathing with CPAP in avoiding death and chronic lung disease (CLD) in very immature infants with a gestational age of less than 27 weeks.
NCT00751959 ↗ Surfactant Application During Spontaneous Breathing With Continuous Positive Airway Pressure (CPAP) in Premature Infants < 27 Weeks Completed German Federal Ministry of Education and Research N/A 2009-04-01 This study investigates the efficacy of surfactant application during spontaneous breathing with CPAP in avoiding death and chronic lung disease (CLD) in very immature infants with a gestational age of less than 27 weeks.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Curosurf

Condition Name

Condition Name for Curosurf
Intervention Trials
Respiratory Distress Syndrome 10
Respiratory Distress Syndrome, Newborn 5
Bronchopulmonary Dysplasia 4
COVID-19 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Curosurf
Intervention Trials
Respiratory Distress Syndrome, Newborn 19
Respiratory Distress Syndrome, Adult 19
Respiratory Distress Syndrome 19
Syndrome 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Curosurf

Trials by Country

Trials by Country for Curosurf
Location Trials
United States 38
Italy 20
France 3
Germany 1
Turkey 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Curosurf
Location Trials
Michigan 4
Massachusetts 3
California 2
Pennsylvania 2
Texas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Curosurf

Clinical Trial Phase

Clinical Trial Phase for Curosurf
Clinical Trial Phase Trials
Phase 4 6
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Curosurf
Clinical Trial Phase Trials
Completed 9
Unknown status 4
Recruiting 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Curosurf

Sponsor Name

Sponsor Name for Curosurf
Sponsor Trials
Chiesi Farmaceutici S.p.A. 7
University of Florence 2
University of Michigan 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Curosurf
Sponsor Trials
Other 54
Industry 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
McKesson
AstraZeneca
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.